Publications by authors named "Jang Young Wang"
Article Synopsis
- The LASER201 study analyzed the effectiveness and safety of lazertinib 240 mg as a first-line treatment for patients with EGFR-mutated non-small cell lung cancer (NSCLC) who had not undergone prior EGFR tyrosine kinase inhibitor therapy.
- Out of 43 participants, the study found a 70% objective response rate and an 86% disease control rate, with a median duration of response and progression-free survival of 23.5 months and 24.6 months, respectively.
- The treatment had a tolerable safety profile, with the most common side effects being rash and diarrhea, while no severe drug-related side effects were reported, indicating a long-term
